European ophthalmologists debate
European Ophthalmology, the social networking group for European ophthalmologists created and moderated by Ophthalmology Times Europe, has recently launched its new discussion forum.
European Ophthalmology, the social networking group for European ophthalmologists created and moderated by Ophthalmology Times Europe, has recently launched its new discussion forum.
We at Ophthalmology Times Europe want to know what you think on a variety of issues that impact directly on your community. A selection of the discussion comments posted will be published in a new feature in the magazine, starting next month. As the voice of the European ophthalmology community, we’d like to represent your views accurately, so your comments will be completely free from censorship: please feel free to discuss your opinions at will.
European Ophthalmology and Ophthalmology Times Europe have no material interest in these discussions: we merely wish to stimulate debate within the industry, and find out how you feel about issues affecting your industry, so that we can accurately represent and respond to your needs.
To become a member of our online community, please go to www.oteurope.com/forum. If you are already a member, please go to www.oteurope.com/discuss to start your own or join in with any of our current discussions.
In conjunction with the debates that we are running, we are also conducting a series of brief surveys (right), so even if your time is limited, you can still make your opinion count, simply at the touch of a button.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach
August 4th 2025In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction
